Rituximab Products

Description

Rituximab humanised monoclonal antibody is a therapeutic reagent directed against the human CD20 cell surface antigen. Rituximab is a therapeutic reagent directed against the human CD20 cell surface antigen. This antibody has been used to detect Rituximab bound to the surface of the Raji B cell line, however detection of Rituximab bound 'in vivo' to B CLL cells has not been demonstrated. It is possible that complement deposition on Rituximab opsonised cells inhibits binding of the anti-Rituximab antibody to cell bound Rituximab.

Bioinformatics

Alternate Names

B lymphocyte antigen CD20 B lymphocyte antigen CD20 B lymphocyte antigen CD20 B lymphocyte surface antigen B1 B lymphocyte surface antigen B1 B lymphocyte surface antigen B1 Bp35 Bp35 Bp35 CD20 CD20 CD20 LEU 16 LEU 16 LEU 16 LEU16 LEU16 LEU16 Membrane spanning 4 domains subfamily A member 1 Membrane spanning 4 domains subfamily A member 1 Membrane spanning 4 domains subfamily A member 1 MS4A1 MS4A1 MS4A1

Research Areas for Rituximab

Find related products by research area and learn more about each of the different research areas below.

Adaptive Immunity
CD Markers
Cell Biology
Cytokine Research
Immunology
Signal Transduction
Stem Cell Markers